BR112013012156A2 - sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico - Google Patents

sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico

Info

Publication number
BR112013012156A2
BR112013012156A2 BR112013012156A BR112013012156A BR112013012156A2 BR 112013012156 A2 BR112013012156 A2 BR 112013012156A2 BR 112013012156 A BR112013012156 A BR 112013012156A BR 112013012156 A BR112013012156 A BR 112013012156A BR 112013012156 A2 BR112013012156 A2 BR 112013012156A2
Authority
BR
Brazil
Prior art keywords
therapeutic system
transdermal therapeutic
producing
transdermal
therapeutic
Prior art date
Application number
BR112013012156A
Other languages
English (en)
Inventor
Fleschhut Jens
Lauer Karin
Feinaeugle Susanne
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43728780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013012156(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of BR112013012156A2 publication Critical patent/BR112013012156A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
BR112013012156A 2010-11-17 2011-11-17 sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico BR112013012156A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10014713 2010-11-17
PCT/EP2011/005784 WO2012065740A1 (en) 2010-11-17 2011-11-17 Transdermal therapeutic system comprising buprenorphine

Publications (1)

Publication Number Publication Date
BR112013012156A2 true BR112013012156A2 (pt) 2017-12-05

Family

ID=43728780

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012156A BR112013012156A2 (pt) 2010-11-17 2011-11-17 sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico

Country Status (9)

Country Link
US (2) US9844515B2 (pt)
EP (1) EP2640389B1 (pt)
CN (1) CN103200944B (pt)
AU (1) AU2011331511C1 (pt)
BR (1) BR112013012156A2 (pt)
CA (1) CA2815898C (pt)
DK (1) DK2640389T3 (pt)
ES (1) ES2528650T3 (pt)
WO (1) WO2012065740A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2008153611A2 (en) 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104736176B (zh) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
TW201431572A (zh) 2012-12-21 2014-08-16 Teikoku Pharma Usa Inc 荷爾蒙及其它醫藥劑之經皮傳遞的組成物及方法
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2938391B1 (en) * 2012-12-28 2022-07-27 Teikoku Seiyaku Co., Ltd. Extended buprenorphine transdermal delivery compositions
ES2599802T3 (es) * 2013-06-04 2017-02-03 Lts Lohmann Therapie-Systeme Ag Sistema de administración transdérmica
EP3019130A4 (en) * 2013-07-10 2016-12-14 Jie Zhang DRUG-PROLONGED TRANSDERMAL RELEASE KIT USING LIQUID OR SEMI-SOLID COMPOSITIONS AND METHOD OF USING THE SAME
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
RU2658463C2 (ru) 2013-10-07 2018-06-21 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для лечения синдрома дефицита внимания и гиперактивности, тревожности и бессонницы с применением трансдермальных композиций на основе дексмедетомидина
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
TWI629061B (zh) * 2013-10-07 2018-07-11 美商帝國製藥美國股份有限公司 包含右美托嘧啶（ｄｅｘｍｅｄｅｔｏｍｉｄｉｎｅ）經皮組成物之疼痛處理用方法及組成物
TWI645866B (zh) 2013-10-07 2019-01-01 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
AR098771A1 (es) * 2014-12-16 2016-06-15 Amarin Tech S A Un dispositivo para la administración transdérmica de rotigotina
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
EP3067050A1 (en) * 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2018526415A (ja) * 2015-09-14 2018-09-13 アムニール ファーマシューティカルズ エルエルシー 経皮送達システム
AR102214A1 (es) * 2015-10-08 2017-02-15 Amarin Tech S A Un dispositivo para la administración transdermal de buprenorfina
WO2017172603A1 (en) * 2016-03-28 2017-10-05 Tioga Research, Inc. Topical formulation
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11541018B2 (en) 2016-06-23 2023-01-03 Corium, Llc Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
EP3490540A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Sodium bicarbonatein situ
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
DE102017112543A1 (de) * 2017-06-07 2018-12-13 Amw Gmbh Overtape für ein transdermales Darreichungssystem
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102255560B1 (ko) 2018-02-20 2021-05-24 주식회사 엘지화학 점착제 조성물 및 이를 포함하는 점착 필름
WO2019175096A1 (en) * 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
US20210275467A1 (en) * 2018-07-09 2021-09-09 Tyme, Inc Tumor reduction formulations and methods of use thereof
WO2021007584A1 (en) * 2019-07-11 2021-01-14 Henkel IP & Holding GmbH Acrylic polymer and adhesive compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (pt) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
ES2115231T3 (es) 1993-04-20 1998-06-16 Hexal Ag Emplasto con sustancias activas.
US6344211B1 (en) * 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
WO2005081825A2 (en) 2004-02-23 2005-09-09 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
DE102004020463A1 (de) 2004-04-26 2005-11-10 Grünenthal GmbH Wirkstoffabgabesystem aus einem wirkstoffhaltigen Pflaster und mindestens einem Wirkstoffabgaberegulierungsmittel

Also Published As

Publication number Publication date
US20180042861A1 (en) 2018-02-15
DK2640389T3 (en) 2015-03-09
EP2640389B1 (en) 2014-12-31
WO2012065740A1 (en) 2012-05-24
AU2011331511C1 (en) 2018-01-18
CA2815898C (en) 2018-12-18
EP2640389A1 (en) 2013-09-25
AU2011331511A1 (en) 2013-05-30
US9844515B2 (en) 2017-12-19
CN103200944B (zh) 2016-05-04
US20130331803A1 (en) 2013-12-12
AU2011331511B2 (en) 2016-04-07
ES2528650T3 (es) 2015-02-11
CN103200944A (zh) 2013-07-10
CA2815898A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
BR112013012156A2 (pt) sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico
SMT201700016B (it) Sistema e procedimento di profilazione di un conducente
CO7000779A2 (es) Sistema de administración transdermica
BR112014032458A2 (pt) curativos médicos e método de prender um dispositivo médico
BR112013021984A2 (pt) métodos e sistema de tratamento de poço
BR112013028133A2 (pt) método e sistema de reconstrução de informações de ativação cardíaca e método de tratamento de um distúrbio de ritmo cardíaco
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
BR112013018981A2 (pt) sistema e método
BR112013021333A2 (pt) sistema médico e método para um procedimento médico
BR112013022764A2 (pt) sistema médico e método
BR112013022949A2 (pt) dispositivo e métodos de microagulha
BR112014013743A2 (pt) sistema e método
BR112012009265A2 (pt) dispositivo de interface de paciente e metodo de ajuste de um dispositivo de interface de paciente
EP2709948A4 (en) METHOD FOR THE SELECTIVE ANCHORING AND RELIEF OF LARGE NUMBER OF NANOSCAL STRUCTURES
EP2720748A4 (en) TRANSDERMAL DRUG DELIVERY SYSTEM AND METHOD OF USE THEREOF
BR112012017067A2 (pt) método e sistema de associação rede-aplicativo
BR112014013600A2 (pt) sistema e método
CO6970579A2 (es) Sistema y método para tratar una actividad de excavación
BR112013017063A2 (pt) sistema de áudio e método de operação de um sistema de áudio
BR112012033536A2 (pt) sistema de esterilização através de chuveiro e método de utilização
BR112013004661A2 (pt) sistema submarino e método de operação de um sistema submarino
SI2468274T1 (sl) Transdermalni terapevtski sistem za dajanje aktivne snovi
BR112014009638A2 (pt) método de perfilagem e sistema de perfilagem
FI20105623A0 (fi) Menetelmä maaperäaineksen käsittelemiseksi
ITMI20120367A1 (it) Procedimento e sistema per produrre un filone-filtro

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]